Why Haemonetics Corporation (NYSE:HAE) Is In News?


Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $35.00 on Haemonetics Corporation (NYSE:HAE) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $1.44 for the next fiscal and $N/A for underway quarter.

Valuation Estimates

Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Haemonetics Corporation (NYSE:HAE) stands at N/A.

Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Haemonetics Corporation Common , the PEG ratio for coming 3-5 years is 5.00.

Technical Analysis

The technical analysis highlights that Haemonetics Corporation Common current is trading $5.02 points away or +16.08% from its 50-day moving average of $31.23. Further it is trading $4.85 or +15.45% away its 200-day moving average of $31.40.

The 52-week high of Haemonetics Corporation (NYSE:HAE) was $39.78 while lowest point recorded in 52-week was $25.98. It implies if stock price makes a movement of over $-3.53, it will record a new 52-week high. In the case of +39.53% drop, it will touch a new 52-week low.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 32 times, 1 visits today)